Choreo LLC’s iShares US Medical Devices ETF IHI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$669K Sell
13,378
-976
-7% -$49.5K 0.01% 830
2026
Q1
$771K Buy
14,354
+1,437
+11% +$84.4K 0.01% 731
2025
Q4
$809K Buy
12,917
+175
+1% +$10.8K 0.01% 690
2025
Q3
$766K Sell
12,742
-316
-2% -$19.3K 0.01% 721
2025
Q2
$818K Sell
13,058
-3,072
-19% -$185K 0.01% 658
2025
Q1
$971K Sell
16,130
-288
-2% -$17.9K 0.02% 568
2024
Q4
$958K Sell
16,418
-2,180
-12% -$130K 0.01% 596
2024
Q3
$1.09M Sell
18,598
-398
-2% -$22.7K 0.02% 541
2024
Q2
$1.05M Sell
18,996
-429
-2% -$24K 0.02% 515
2024
Q1
$1.14M Buy
19,425
+810
+4% +$45.7K 0.03% 246
2023
Q4
$1M Sell
18,615
-3,166
-15% -$155K 0.03% 262
2023
Q3
$1.06M Sell
21,781
-2,427
-10% -$129K 0.04% 191
2023
Q2
$1.37M Sell
24,208
-857
-3% -$47.2K 0.05% 174
2023
Q1
$1.35M Buy
+25,065
New +$1.33M 0.05% 184

Other funds holding IHI

Choreo LLC's IHI Position: Q2 2026 in Review

Choreo LLC reduced its iShares US Medical Devices ETF (IHI) stake by 6.8% in Q2 2026, selling an estimated $49.5K and leaving 13,378 shares worth $669K. The position accounts for 0.01% of the portfolio, ranked #830.

Choreo LLC first reported a position in IHI in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.37M in Q2 2023. 501 funds tracked by Wall St. Rank hold IHI as of Q2 2026.

  • Choreo LLC held 13,378 shares of iShares US Medical Devices ETF worth $669K as of Q2 2026.
  • Choreo LLC sold 976 iShares US Medical Devices ETF shares in Q2 2026, an estimated $49.5K.
  • iShares US Medical Devices ETF made up 0.01% of Choreo LLC's portfolio in Q2 2026, its #830 holding.
  • Choreo LLC first reported a position in iShares US Medical Devices ETF in Q1 2023 and has held it in 14 quarters since.
  • Choreo LLC's iShares US Medical Devices ETF position peaked at $1.37M in Q2 2023.
  • 501 funds tracked by Wall St. Rank held iShares US Medical Devices ETF as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.